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Introduction
Platelet-rich-plasma (PRP) is an autologous con-
centration of platelets in plasma developed by gradient 
density centrifugation. It has been increasingly used in 
a variety of medical fields. The effectiveness of this pro-
cedure lies in the delivery, up on stimulation, of a wide 
range of platelet growth factors mimicking the physio-
logic wound healing and reparative tissue processes 
(Werner and Grose, 2003). Current evidence suggests 
that platelets have multiple functional attributes indica-
tive of an integral role in antimicrobial host defense 
(Yeaman et al., 1998; Tang et al., 2002). These functions 
include navigation toward the inflammatory chemoat-
tractant N-f-etLeuPhe, expression of Fc and comple-
ment C3a/C5a receptors, and the capacity to generate 
antimicrobial oxygen metabolites. Platelets interact 
directly with microorganisms, contribute to clearance 
of pathogens from the bloodstream, and significantly 
participate in antibody dependent cell cytotoxicity 
against microbial pathogens (Yeaman, 1997; Yeaman 
and Bayer, 1999). Moreover, platelet α-granules contain 
catecholamines, serotonin, osteonectin, von Willebrand 
factor, proaccelerin and other substances (Anitua et al., 
2005; Bielecki et al., 2006). These are released in high 
concentrations after platelet aggregation and may also 
have antibacterial effects. Yeaman et al. (1998) and 
Tang et al. (2002) had shown that platelet microbicidal 
proteins released after platelet activation demonstrate 
potent activities against many gram-negative, gram-
posi tive and fungal pathogens. Collectively, these find-
ings suggest that human platelets possess, and can be 
stimu lated to release, several antimicrobial polypeptides 
(Krijgsveld et al., 2000). The antimicrobial potential of 
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A b s t r a c t
Antimicrobial properties of platelet rich plasma (PRP) against various microorganisms have been recently pointed out. PRP could be an 
alternative to conventional antibiotics in preventing oral and periodontal infections. We examined whether PRP has in vitro antimicrobial 
properties against Aggregatibacter actinomycetemcomitans, Prophyromonas gingivalis, Staphylococcus aureus and Candida albicans. PRP 
and platelet-poor plasma (PPP) were obtained from whole blood of 10 healthy volunteers and 10 periodontitis patients. In vitro laboratory 
susceptibility was carried out using the modified agar diffusion method by measuring the diameters of inhibition zones on agar plates 
coated with selected microbial strains. Both calcium chloride (CaCl2) activated and non activated samples were tested. Both activated PRP 
and PPP, of both patients and controls, effectively inhibited the growth of A. actinomycetemcomitans, P. gingivalis and C. albicans. However, 
a statistically significant difference in favor of PRP was found indicating more susceptibility to PRP than PPP (p < 0.05). Non activated PRP 
and PPP exhibited negative zones of inhibition against the studied microorganisms. There was no activity against S. aureus. No statistically 
significant difference was found between the antimicrobial effects of PRP and/or PPP obtained from patients and controls (p > 0.05). We 
conclude that PRP is a potentially useful substance against oral and periodontal pathogens. Activated PRP was found to be more active 
than activated PPP and the activation of coagulation is a fundamental step. Additionally, the antimicrobial activity of PRP and/or PPP 
seems not to be affected by periodontitis.
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platelets might be increased through their concentra-
tion in PRP (Drago et al., 2013).
Despite extensive use in clinical procedures, only 
few studies have investigated PRP’s microbicidal activity 
(Bielecki et al., 2007; Moojen et al., 2008; Anitua et al., 
2012; Burnouf et al., 2013; Drago et al., 2013). Mariani 
et al. (2015) tested the effect of PRP against Escheri­
chia coli, Staphylococcus aureus, Klebsiella pneumoniae, 
Pseudomonas aeruginosa and Enterococcus faecalis, as 
species potentially involved in bone, soft tissue and 
wound infections (Zalavras et al., 2004). In the current 
study, we have selected four microorga nisms that are 
commonly found in oral and periodontal infections 
and investigated whether PRP could have in vitro anti-
microbial effects against them.
Aggregatibacter actinomycetemcomitans and Porphy­
romonas gingivalis are major periodontal pathogens. 
A. actinomycetemcomitans is a nonmotile, capnophilic, 
Gram-negative, coccobacillus, and a facultative anae-
robe. P. gingivalis is a nonmotile, coccobacillus, and an 
obligate anaerobe. Both pathogens produce a  num-
ber of virulence factors and damaging metabolites 
that are associated with initiation and progression of 
periodontal destruction. Adjunctive antimicrobial the- 
rapy along with appropriate mechanical therapy helped 
in the elimi nation of these pathogens. The linking of 
the inductive and antimicrobial effects of PRP may 
be beneficial for the treatment of periodontal disease 
(Teles et al., 2006).
S. aureus has been associated with dentoalveolar 
infections and oral mucosal lesions. Studies suggested 
that the presence of S. aureus in saliva was a significant 
risk factor for aspiration pneumonia (Terpenning et al., 
2001; El-Solh et al., 2004). Oral S. aureus may also serve 
as a reservoir for cross-infection to other patients, as 
well as health care staff (Smith et al., 2003). Addition-
ally, some studies have demonstrated that S. aureus 
plays a role in exacerbating dental diseases by forming 
a  biofilm with the causative pathogens of periodon- 
tal diseases (Smith et al., 2001; Cuesta et al., 2010; 
Passa riello et al., 2012).
Oral candidiasis is the most common fungal infec-
tion encountered in general dental practice. It manifests 
in a variety of clinical presentations and can occasion-
ally be refractory to treatment. It is caused by commen-
sal Candida species. The most commonly implicated 
strain is C. albicans which is isolated in over 80% of oral 
candidal lesions (Farah et al., 2010).
The development of new, cost-effective and safe 
measures to prevent and control oral and periodon- 
tal infections is important. The present study was 
undertaken to test the in vitro antimicrobial activity 
of activated and non activated PRP and PPP against 
A. actinomycetemcomitans, P. gingivalis, S. aureus and 
C. albicans.
Experimental
Materials and Methods
Study design and donors. The study was conducted 
in compliance with good clinical practice guidelines 
and the Declaration of Helsinki. The subjects of this 
study were pa tients who visited the outpatient clinic 
of the Faculty of Dentistry, October 6 University. Ten 
patients diagnosed with generalized chronic periodon-
titis (Armitage, 1999) (mean age ± SD:  45.2 ± 3.1 years) 
and ten periodontally healthy subjects with no clinical 
attachment loss and a probing pocket depth less than 
or equal to 3mm (mean age ± SD: 42.7 ± 3.4  years) 
were included. All subjects received verbal and written 
information about the study and signed consent forms 
before enrollment in the study. Criteria for exclusion 
were the use of antibiotics or other antimicrobial and/ 
or anti-inflammatory medicaments during the previous 
3 months, smoking, pregnancy, suffering from systemic 
disorders and/or presence of infection. Subjects with 
hemoglobin concentrations < 11 g/dl and platelet num-
bers ≤ 150 × 103/μl, were also excluded from the study. 
Collection of samples. Sub-gingival samples were 
taken from the ten chronic periodontitis patients after 
rinsing the mouth with distilled water. Samples from 
the sub-gingival pockets were collected with a Gracey 
7/8 curette, after relatively isolating the zone with cot-
ton rolls and high-power suction and removing supra 
gingival biofilm. Each patient contributed a total of 
four samples collected from the deepest pocket of each 
patient’s dentition quadrant. Samples from all patients 
(40  samples) were placed in sterile PBS (phosphate 
buffer solution, pH 7.4) transport medium, and kept 
at –4°C until processing. The samples were processed 
within 6 hours.
Microbiological procedures. The isolates were all 
purified and identified to species level. Tenfold serial 
dilutions were prepared in sterile phosphate buffered 
saline. Appropriate dilutions were plated onto non-
selective 5% horse blood agar plates (Oxoid no. 2; 
Oxoid Ltd, Basingstoke, England) supplemented with 
haemin (5 Fg/l) and menadione (1 Fg/l) (BA), and on 
trypticase soy-serum bacitracin-vancomycin (TSBV) 
plates (Slots, 1982) for selective isolation and growth of 
A. actinomycetemcomitans. TSBV plates were incubated 
at 35°C in 10% CO2/90% N2 for 4 days. 
Identification of isolates. Microscope studies with 
Gram coloring and biochemical tests were used to iden-
tify the microorganisms. Identification of A. actino­
mycetemcomitans and P. gingivalis isolates was carried 
out using the criteria and techniques of Slots (1986; 
1987). P. gingivalis was identified based on microscopic 
morphology, Gramreaction and detection of a trypsin-
like activity based on the degradation of benzoyl-DL-
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arginine-2-naphthylamide (Sigma, St Louis, MO, USA) 
(van Winkelhoff et al., 1988). Identification of A. actino­
mycetemcomitans was based on the characteristic 
colony morphology (star-like inner structure) on the 
TSBV plate, and a positive catalase reaction upon expo-
sure to 3% H2O2. S. aureus were grown in plates con-
taining Mannitol Salt Agar (Becton Dickinson, USA) 
and was identified in this media by the production of 
golden color zones around the colonies. Additionally, 
catalase and coagulase tests were performed (Murray 
et al., 1999). 
For the isolation and identification of C. albicans, we 
used the exhaustion technique in plates of chromogenic 
agar media, CandiSelect (Bio-Rad, France), which is 
a specific culture media for the growth of yeasts. Blue 
colonies were identified as C. albicans. 
Platelet rich plasma preparation. PRP was pre-
pared following a one-step procedure according to 
Anitua’s protocol (Anitua et al., 2008). Peripheral blood 
(4.5 ml) from each donor was taken by venipuncture 
into 5 ml blood-collecting tubes containing 0.5 ml 
of sodium citrate solution (3.8%) as anticoagulan 
and centrifuged using a laboratory centrifuge (Centu-
rion, Scientific limited, UK) at 460 × g for 8 min, thus 
obtaining three layers: platelet-poor plasma (PPP) on 
the top of the tube, PRP in the middle and erythro- 
cytes at the bottom of the tubes. Subsequently, PPP 
component was removed. PRP, located on the red 
blood cell pellet, was carefully harvested avoiding leu-
kocyte collection. The platelet and leukocyte counts 
in the peripheral blood, PRP and PPP were measured 
automatically using a hematology analyzer. According 
to Anitua et al. (2008) platelet concentration in PRP is 
at least twice the concentration in whole blood; while 
leukocyte concentration is consistently lower (< 103 
white blood cells/μl). Platelets should be almost absent 
in PPP. PRP and PPP were activated shortly before use 
by the addition of 10% calcium chloride (50 μl per ml 
of PRP or PPP).
Determination of antimicrobial activity. Anti-
micro bial activity of PRP, PPP against A. actinomycetem­
comitans, P. gingivalis, S. aureus and C. albicans were 
carried out according to the modified agar diffusion 
method. Both CaCl2 activated and non activated sam-
ples were tested. Controls were performed using CaCl2 
per se at a final concentration of 4.5 mM. 
An overnight culture of S. aureus and C. albicans 
and three day culture of A. actinomycetemcomitans and 
P. gingivalis were adjusted to reach a cell density of 
approximately 107 to 108 cfu/ml and was surface incul-
cated on BHA plates, then fixed volumes of PRP with 
CaCl2, PPP with CaCl2 and CaCl2 were aseptically 
added, by using separate micropipettes, to cups made in 
these plates. Plates were incubated for 24 h for S. aureus 
and C. albicans at 37°C and for 3–7 days under micro-
aerophilic condition for A. actinomycetemcomitans and 
P. gingivalis. Twenty four hours after incubation, acti-
vity was assessed by measuring the zones of inhibition, 
which were recorded as the diameter in millimetres 
across the centre of the embedded discs.
Fig. 1. Antimicrobial activity of platelet rich plasma against
A. actinomycetemcomitans using disc diffusion method.
Fig. 2. Antimicrobial activity of platelet rich plasma against
P. gingivalis using disc diffusion method.
Fig. 3. Antimicrobial activity of platelet rich plasma and platelet
poor plasma against S. aureus using disc diffusion method.
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Statistical analysis. The data are presented as the 
mean ± SD. Statistical differences were evaluated using 
the Mann-Whitney U test with a p-value ≤ 0.05 consid-
ered to be significant.
Results
No significant difference has been found between 
platelet concentration in PRP pooled blood samples 
of periodontitis patients and controls (p > 0.05). It has 
been found to be about 2.5 times higher than in whole 
blood (Table I). Platelets were almost absent in PPP of 
both patients and controls (< 102 platelets/ml) (Table I). 
All pooled PRP and PPP was efficiently leukocyte-
depleted (< 103 white blood cells/ml).
In vitro antimicrobial activity of PRP and PPP 
(patients and controls) showed that both of them 
effectively inhibited the growth of A. actinomycetem­
comitans, P. gingivalis and C. albicans but not S. aureus. 
A statistically significant difference in favor of PRP has 
been found indicating more susceptibility to PRP than 
PPP (p < 0.05). Only activated samples displayed an 
antimicrobial activity, whereas non activated samples 
did not exhibit any effect, suggesting that the activation 
of coagulation is a fundamental step (Table II, III).
Among the tested microorganisms A. actinomycet­
emcomitans was found to be the most sensitive to both 
PRP and PPP while C. albicans the least. Activated PRP 
of the 10 periodontitis patients exhibited mean zones of 
inhibitions of 29 ± 0.1, 25 ± 0.4 and 20 ± 0.1 mm against 
A. actinomycetemcomitans, P. gingivalis and C. albicans 
respectively. While activated PPP of the same patients 
exhibited mean zones of inhibition of 25 ± 0.4, 18 ± 0.3 
and 17 mm against A. actinomycetemcomitans, P. gingi­
valis and C. albicans respectively (Table II). Activated 
PRP of 10 controls exhibited mean zones of inhibitions 
of 30 ± 0.2, 26 ± 0.6, 19 ± 0.05 mm against A. actinomy­
cetemcomitans, P. gingivalis and C. albicans respectively 
and activated PPP exhibited mean zones of inhibitions 
23 ± 1, 20 ± 1.1 and 15 ± 0.99 mm against A. actinomy­
cetemcomitans, P. gingivalis and C. albicans respectively 
(Table III). Calcium chloride per se exhibited zones of 
inhibitions of 17 ± 03, 12 ± 0.1, 14 ± 0.3 mm against 
Age(years) 45.2 ± 3.1 42.7 ± 3.4 > 0.05
Gender
Male 6 5 > 0.05
Female 4 5
Mean platelet concentration in whole blood (platelets /ml) 215 × 103  210 × 103 > 0.05
Mean platelet concentration in PRP (platelets /ml) 480 × 103 462 × 103 > 0.05
Mean platelet concentration in PPP (platelets /ml) – – > 0.05
Table I
Characteristics of the sample presented as mean ±SD
Variable Periodontitis group(Mean ± SD)
Control group
(Mean ± SD) (p-value)
Fig. 4. Antimicrobial activity of platelet poor plasma and calcium 
chloride against P. gingivalis using disc diffusion method.
Fig. 5. Antimicrobial activity of platelet rich plasma, platelet poor 
plasma and calcium chloride against C. albicans using disc diffu-
sion method.
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A. actinomycetemcomitans, P. gingivalis and C. albicans 
respectively (Table II, III). Activated PRP and Activated 
PPP of patients and controls exhibited negative zone of 
inhibition against S. aureus. 
The difference in the antimicrobial activity between 
PRP and PPP of patients and controls against the stud-
ied microorganisms was not significant (p > 0.05).
Discussion
It is impossible to separate wound healing and infec-
tion. The use of PRP may be advantageous compared 
to conventional antibiotic treatments since PRP is less 
likely to induce antibiotic resistance and PRP’s anti- 
microbial and healing-promoting properties may have 
a synergistic effect on infection prevention. Moreover, 
PRP is inherently biocompatible, and safe. In the current 
study, we tested the antimicrobial activity of PRP, PPP, 
with and without activation against four microorgan-
isms, A. actinomycetemcomitans, P. gingivalis, S. aureus 
and C. albicans. We used samples from both periodon-
tally healthy individuals and patients with chronic 
periodontitis to investigate potential donor variations 
and whether the antimicrobial effect of PRP could be 
affected by the presence of chronic periodontitis.
Although leukocytes have been proposed as an addi-
tional source for cytokines, microbicidal proteins and 
myeloperoxidase activity (Hampton et al., 1996), the few 
available published data do not support the increased 
microbicidal activity of PRP due to the leukocyte com-
ponent (Bielecki et al., 2007; Moojen et al., 2008; Anitua 
et al., 2012). Therefore in this study we used the Anitua’s 
protocol (Anitua et al., 2008) that allows the production 
of leukocyte-poor PRP. Originally bovine thrombin was 
used as an activating agent, but the rare and major risk 
of coagulopathy from antibody formation has restricted 
the routine use of bovine thrombin. Calcium chloride, 
used in the current study, offer an alternative in vitro 
activation means (Anitua, 1999). 
In the current study, we have found that PRP, and 
to a lesser extent, PPP has antimicrobial effects against 
A. actinomycetemcomitans, P. gingivalis and C. albicans 
but not S. aureus. Only activated samples were able to 
inhibit microbial growth, suggesting that the activation 
of coagulation is a fundamental step. No significant dif-
ference was found between in vitro antimicrobial effect 
of PRP and PPP isolated from periodontitis patients 
and healthy controls.
To the best of our knowledge, only Yang et al. (2015) 
have investigated the antimicrobial activity of PRP 
and other plasma preparations against periodontal 
A. actinomycetemcomitans 29 ± 0.1 – 25 ± 0.4 – 17 ± 03 < 0.05
P. gingivalis 25 ± 0.4 – 18 ± 0.3 – 12 ± 0.1 < 0.05
C. albicans 20 ± 0.1 – 17 – 14 ± 0.3 < 0.05
S. aureus – – – – – 
Table II
Microbiological screening for the antimicrobial activity of the activated PRP, activated PPP, non-activated PRP and non-activated PPP 
obtained from 10 periodontitis patients and Cacl2 per se against A. actinomycetemcomitans, P. gingivalis, C. albicans and S. aureus by agar 
diffusion method
– No inhibition zone
Name
of microorganism
Diameter of zone of inhibition ± standard deviation (SD) in mm
Activated
PRP
Non-activated
PRP
Activated
PPP
Non-activated
PPP Cacl2
PRP vs PPP
(p-value)
A. actinomycetemcomitans 30 ± 0.2 – 23 ± 1 – 17 ± 03 < 0.05
P. gingivalis 26 ± 0.6 – 20 ± 1.1 – 12 ± 0.1 < 0.05
C. albicans 19 ± 0.05 – 15 ± 0.99 – 14 ± 0.3 < 0.05
S. aureus – – – – –
Table III
Microbiological screening for the antimicrobial activity of the activated PRP, activated PPP, non-activated PRP and non-activated PPP 
obtained from 10 controls and Cacl2 per se against A. actinomycetemcomitans, P. gingivalis, C. albicans and S. aureus by agar diffusion 
method
– No inhibition zone
Name
of microorganism
Diameter of zone of inhibition ± standard deviation (SD) in mm
Activated
PRP
Non-activated
PRP
Activated
PPP
Non-activated
PPP Cacl2
PRP vs PPP
(p-value)
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pathogens. The authors found that all plasma prepara-
tions can inhibit bacterial growth, with PRP showing 
the superior activity. In the current study, the activity of 
PRP against A. actinomycetemcomitans and P. gingivalis 
is comparable to that of Yang et al. (2015). These results 
confirm the beneficial role of PRP in the treatment of 
periodontal disease.
 Activated PRP and activated PPP didn’t inhibit the 
growth of S. aureus. These results are contradictory to 
those obtained by Bielecki et al. (2007). They performed 
a microbiological examination of PRP on 20 healthy 
volunteers; a strong activity comparable to gentamicin 
and oxacillin for PRP against methicillin-sensitive 
S. aureus was demonstrated. According to the former 
authors, PRP also inhibited the growth of methicillin 
–  resistant S. aureus and Escherichia coli. Moreover, 
a study by Moojen et al. (2008) investigated the effect 
of various platelet concentrate on S. aureus, they found 
a  strong effect of PRP activated by thrombin (PLG) 
but not non activated PRP. They concluded that the 
decrease in microbial load is mainly attributed to the 
effect of activation by thrombin. However, they found 
that the strong antimicrobial effect of PLG seems to be 
limited to the first hours after application. Additionally, 
Jia et al. (2010) reported that PRP forms into PLG after 
activation with bovine thrombin can inhibit S. aureus 
reproduction in vitro and can effectively prevent bone 
infection in vivo. The reasons for the inconsistency 
between their results and the results of the current study 
may be explained by differences in the bacterial isolates 
and the increased frequency of antimicrobial use in 
mi nor surgical procedures which may lead to increased 
antimicrobial resistance in our population. Additionally, 
in the current study, CaCl2, which may have a weaker 
and more prolonged activation time, has been used for 
activation instead of thrombin (Li et al., 2013). Moreo-
ver, the different protocol used for PRP preparation can 
lead to products with different cellular components and 
biological characteristics. The difference in the sensi-
bility of the method (modified agar diffusion method) 
used to evaluate the susceptibility to platelet concen- 
trate should also be considered (Ehrenfest et al., 2013; 
Assirelli et al., 2014; Cavallo et al., 2014).
Another important obtained result is the observa-
tion that PRP and PPP were less active against C. albi­
cans than against A. actinomycetemcomitans and P. gin­
givalis. This result is consistent with the findings of Tang 
et al. (2002), who tested in vitro antimicrobial activity of 
antimicrobial peptides isolated from human platelets, 
and noticed that they were more potent against bacteria 
than fungi. 
In contrary to Li et al. (2013) study, PPP has demon-
strated antimicrobial effect. However, a greater suscep-
tibility for activated PRP was observed. The antimicro-
bial effect of PPP might be explained by the presence 
of antimicrobial peptides and other factors in plasma, 
either released from the platelets during normal func-
tioning or by breakdown of some platelets during the 
blood processing (Wu et al., 1994). 
Future research should focus on the analysis of the 
contribution of individual PRP and PPP components, 
its antimicrobial capacity compared to antibiotics and 
its exact antibacterial spectrum. Moreover, despite the 
clinical relevance of these results, it is clear that the in 
vitro behavior of bacterial plates may not mimic the in 
vivo environment of the oral cavity and in vitro sus-
ceptibility to antimicrobials should only be regarded as 
a guide to potential in vivo activities. Future clinical tri-
als should be done to investigate the potential practical 
implications of the findings of this study as well as the 
modality of clinical application of platelet concentrates.
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